Matches in UGent Biblio for { <https://biblio.ugent.be/publication/742245#aggregation> ?p ?o. }
Showing items 1 to 33 of
33
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B333476.
- aggregation creator B333477.
- aggregation creator B333478.
- aggregation creator B333479.
- aggregation creator B333480.
- aggregation date "2007".
- aggregation format "application/pdf".
- aggregation hasFormat 742245.bibtex.
- aggregation hasFormat 742245.csv.
- aggregation hasFormat 742245.dc.
- aggregation hasFormat 742245.didl.
- aggregation hasFormat 742245.doc.
- aggregation hasFormat 742245.json.
- aggregation hasFormat 742245.mets.
- aggregation hasFormat 742245.mods.
- aggregation hasFormat 742245.rdf.
- aggregation hasFormat 742245.ris.
- aggregation hasFormat 742245.txt.
- aggregation hasFormat 742245.xls.
- aggregation hasFormat 742245.yaml.
- aggregation isPartOf urn:issn:0140-7783.
- aggregation language "eng".
- aggregation title "Pharmacokinetic-pharmacodynamic integration of danofloxacin after intravenous, intramuscular and subcutaneous administration to rabbits".
- aggregation abstract "The pharmacokinetics of danofloxacin was studied following intravenous (i.v.), intramuscular (i.m.) and subcutaneous (s.c.) administration of 6 mg/kg to healthy rabbits. Danofloxacin concentration were determined by high-performance liquid chromatography assay with fluorescence detection. Minimal inhibitory concentrations (MICs) assay of danofloxacin against 30 strains of Staphylococcus aureus from several European countries was performed in order to compute pharmacodynamic surrogate markers. The danofloxacin plasma concentration versus time data after i.v. administration could best be described by a two-compartment open model. The disposition of i.m. and subcutaneously administered danofloxacin was best described by a one-compartment model. The terminal half-life for i.v., i.m. and s.c. routes was 4.88, 6.70 and 8.20 h, respectively. Clearance value after i.v. dosing was 0.76 L/kg.h. After i.m. administration, the absolute bioavailability was mean (+/- SD) 102.34 +/- 5.17% and the C-max was 1.87 mg/L. After s.c. administration, the absolute bioavailability was mean (+/- SD) 96.44 +/- 5.95% and the C-max was 1.79 mg/L. Danofloxacin shows a favourable pharmacokinetics profile in rabbits reflected by parameters such as a long half-life and a high bioavailability. However, in consideration of the low AUC/MIC indices obtained, its use by i.m. and s.c. route against the S. aureus strains assayed in this study cannot be recommended given the risk for selection of first mutant subpopulations.".
- aggregation authorList BK628631.
- aggregation endPage "24".
- aggregation issue "1".
- aggregation startPage "18".
- aggregation volume "30".
- aggregation aggregates 763416.
- aggregation isDescribedBy 742245.
- aggregation similarTo LU-742245.